Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced a final cash dividend of RMB 0.32 per share for the financial year ending December 31, 2024, with shareholders’ approval obtained on June 24, 2025. The dividend will be paid in Hong Kong dollars at HKD 0.35 per share, with the ex-dividend date set for July 24, 2025, and payment on August 22, 2025. The announcement also detailed withholding tax rates applicable to different types of shareholders, impacting non-resident enterprises and individuals, as well as mainland investors through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacture, and distribution of pharmaceutical products. The company is known for its diverse range of healthcare solutions and has a significant market presence in both domestic and international markets.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.